Patent application number | Description | Published |
20090011160 | Polymeric Packaging Film - A polymeric film has at least one surface on which chitosan has been immobilised so as to be substantially resistant to leaching and have a strong antimicrobial activity. The polymeric film may be a polyolefin film such as a biaxially orientated polypropylene film. A process immobilises chitosan on a polymeric surface so as to be resistant to leaching and have a strong antimicrobial activity by applying chitosan to a polymeric film surface which has been activated before addition of chitosan to the surface by plasma activation at atmospheric pressure. | 01-08-2009 |
20100215878 | INK COMPOSITION, OXYGEN AND/OR pH INDICATOR AND PACKAGE - The invention concerns an ink composition comprising an oxidizing and reducing agent and/or pH colorant as the dye, polymeric material as the binder, as well as a pH adjuster and volatile solvent. Further, the invention concerns a method for manufacturing an oxygen and/or pH indicator, in which the ink composition is printed and reduced, or reduced using a volatile reducer and printed; an oxygen and/or pH indicator manufactured by the method, as well as a package for stating a leakage, a change caused by oxygen content and/or deterioration of a product. | 08-26-2010 |
20100300467 | SMOKING ARTICLE - The invention relates to a smoking article comprising tobacco, suction resistance and a chemical heat source in conjunction with the tobacco. According to the invention, the heat source comprises a heat chamber and is activated by external excitation. The invention relates further to a method for producing the smoking article. | 12-02-2010 |
20110136238 | OXYGEN INDICATOR - The invention relates to a dye composition comprising a dye, dye converter, binder, reducing agent, solvent and optionally basic agent. Further, the invention relates to a method for fabricating an oxygen indicator wherein a dye composition is applied over a substrate and reduced by heating, to an oxygen indicator fabricated by the method and to a package for detecting a leakage and/or variation in the oxygen content. | 06-09-2011 |
20110214600 | INDICATOR - The invention relates to an indicator comprising a substrate and an optical grating structure fabricated on the substrate, the grating structure being formed from an indicator material comprising a binder and deliquescent salt and varying in volume by the effect of moisture. Further, the invention relates to a method for fabricating an indicator wherein a substrate is coated by an indicator material forming an optical grating structure, and the optical grating structure is fabricated onto the substrate, and use of an indicator for detecting quality and/or authenticity. Furthermore, the invention relates to a package and a method for detecting a change induced by moisture without breaking the package. | 09-08-2011 |
20120041887 | METHOD AND ARRANGEMENT FOR RETRIEVING INFORMATION RELATED TO A PRODUCT - An arrangement for enabling an acting party, e.g. a natural person or an automatic inspection line, to retrieve information from a product ( | 02-16-2012 |
20130017609 | APPARATUS AND METHOD FOR INDICATING A PHYSICAL OR CHEMICAL PHENOMENONAANM Kansakoski; MarkkuAACI OuluAACO FIAAGP Kansakoski; Markku Oulu FIAANM Hurme; EeroAACI EspooAACO FIAAGP Hurme; Eero Espoo FIAANM Hakalahti; LeenaAACI OuluAACO FIAAGP Hakalahti; Leena Oulu FIAANM Korhonen; RaimoAACI TampereAACO FIAAGP Korhonen; Raimo Tampere FIAANM Kemppainen; AnttiAACI OuluAACO FIAAGP Kemppainen; Antti Oulu FI - The invention relates to an apparatus ( | 01-17-2013 |
Patent application number | Description | Published |
20120258123 | BIOMARKERS FOR SENSITIVE DETECTION OF STATIN-INDUCED MUSCLE TOXICITY - The present invention inter alia provides a method, and uses thereof, of predicting statin-induced muscle toxicity or its complications, such as myalgia, myopathy and rhabdomyolysis, by detecting the lipid concentrations or lipid-lipid concentration ratios of a biological sample and comparing them to a control. This method has identified lipid markers that are more specific and sensitive in detecting these statin-induced muscle toxicity than the currently utilized clinical markers. Also provided is an antibody towards said lipids, and the use thereof for predicting, diagnosing, statin-induced muscle toxicity. The invention additionally relates to kits comprising lipids and/or an antibody thereto, for use in the prediction and/or diagnosis of statin-induced muscle toxicity. | 10-11-2012 |
20130045217 | LIPIDOMIC BIOMARKERS FOR ATHEROSCLEROSIS AND CARDIOVASCULAR DISEASE - The present invention inter alia provides a method, and use thereof, of diagnosing and/or predicting atherosclerosis or CVD by detecting the lipid concentrations or lipid ratios of a biological sample and comparing it to a control and has identified specific lipid markers that are more specific and sensitive in detecting and predicting atherosclerosis and CVD than currently utilized clinical markers. Also provided is an antibody towards said lipids, and the use thereof for predicting, diagnosing, preventing and/or treating atherosclerosis or CVD. The invention additionally relates to kits comprising lipids and/or an antibody thereto, for use in the prediction and/or diagnosis of atherosclerosis or CVD. | 02-21-2013 |
20130216560 | Lipidomic Biomarkers for Identification of High-Risk Coronary Artery Disease Patients - The present invention inter alia provides a method, and use thereof, of predicting severe CVD complications such as AMI or CVD death by detecting the lipid concentrations or lipid ratios of a biological sample and comparing it to a control and has identified specific lipid markers that are more specific and sensitive in predicting these CVD complications than currently utilized clinical markers. Also provided is an antibodies towards said lipids, and the use thereof for predicting, diagnosing, preventing and/or treating CVD complications. The invention additionally relates to kits comprising lipids and/or an antibody thereto, for use in the prediction and/or diagnosis of CVD complications. | 08-22-2013 |
20140031332 | Biomarkers for Sensitive Detection of Statin-Induced Muscle Toxicity - The present invention inter alia provides a method, and uses thereof, of predicting statin-induced muscle toxicity or its complications, such as myalgia, myopathy and rhabdomyolysis, by detecting the lipid concentrations or lipid ratios of a biological sample and comparing it to a control. This method has identified lipid markers that are more specific and sensitive in detecting these statin-induced muscle toxicity than the currently utilized clinical markers. Also provided is an antibody towards said lipids, and the use thereof for predicting, diagnosing, statin-induced muscle toxicity. The invention additionally relates to kits comprising lipids and/or an antibody thereto, for use in the prediction and/or diagnosis of statin-induced muscle toxicity. | 01-30-2014 |
20140295466 | LIPIDOMIC BIOMARKERS FOR THE PREDICTION OF CARDIOVASCULAR OUTCOMES IN CORONARY ARTERY DISEASE PATIENTS UNDERGOING STATIN TREATMENT - The present invention inter alia provides a method, and use thereof, of predicting severe CVD complications such as AMI or CVD death by detecting the lipid concentrations or lipid ratios of a biological sample and comparing it to a control and has identified specific lipid markers that are more specific and sensitive in predicting these CVD complications than currently utilized clinical markers. Also provided are antibodies towards said lipids, and the use thereof for predicting, diagnosing, preventing and/or treating CVD complications. The invention additionally relates to kits comprising lipids and/or an antibody thereto, for use in the prediction and/or diagnosis of CVD complications. | 10-02-2014 |
20140295467 | LIPIDOMIC BIOMARKERS FOR THE PREDICTION OF CARDIOVASCULAR OUTCOMES IN CORONARY ARTERY DISEASE PATIENTS NOT UNDERGOING STATIN TREATMENT - The present invention inter alia provides a method, and use thereof, of predicting severe CVD complications such as AMI or CVD death by detecting the lipid concentrations or lipid ratios of a biological sample and comparing it to a control and has identified specific lipid markers that are more specific and sensitive in predicting these CVD complications than currently utilized clinical markers. Also provided are antibodies towards said lipids, and the use thereof for predicting, diagnosing, preventing and/or treating CVD complications. The invention additionally relates to kits comprising lipids and/or an antibody thereto, for use in the prediction and/or diagnosis of CVD complications. | 10-02-2014 |
20150247873 | LIPIDOMIC BIOMARKERS FOR ATHEROSCLEROSIS AND CARDIOVASCULAR DISEASE - The present invention inter alia provides a method, and use thereof, of diagnosing and/or predicting atherosclerosis or CVD by detecting the lipid concentrations or lipid ratios of a biological sample and comparing it to a control and has identified specific lipid markers that are more specific and sensitive in detecting and predicting atherosclerosis and CVD than currently utilized clinical markers. Also provided is an antibody towards said lipids, and the use thereof for predicting, diagnosing, preventing and/or treating atherosclerosis or CVD. The invention additionally relates to kits comprising lipids and/or an antibody thereto, for use in the prediction and/or diagnosis of atherosclerosis or CVD. | 09-03-2015 |
20150260737 | LIPIDOMIC BIOMARKERS FOR THE PREDICTION OF CARDIOVASCULAR OUTCOMES IN CORONARY ARTERY DISEASE PATIENTS NOT UNDERGOING STATIN TREATMENT - The present invention inter alia provides a method, and use thereof, of predicting severe CVD complications such as AMI or CVD death by detecting the lipid concentrations or lipid ratios of a biological sample and comparing it to a control and has identified specific lipid markers that are more specific and sensitive in predicting these CVD complications than currently utilized clinical markers. Also provided are antibodies towards said lipids, and the use thereof for predicting, diagnosing, preventing and/or treating CVD complications. The invention additionally relates to kits comprising lipids and/or an antibody thereto, for use in the prediction and/or diagnosis of CVD complications. | 09-17-2015 |
20150260738 | LIPIDOMIC BIOMARKERS FOR THE PREDICTION OF CARDIOVASCULAR OUTCOMES IN CORONARY ARTERY DISEASE PATIENTS UNDERGOING STATIN TREATMENT - The present invention inter alia provides a method, and use thereof, of predicting severe CVD complications such as AMI or CVD death by detecting the lipid concentrations or lipid ratios of a biological sample and comparing it to a control and has identified specific lipid markers that are more specific and sensitive in predicting these CVD complications than currently utilized clinical markers. Also provided are antibodies towards said lipids, and the use thereof for predicting, diagnosing, preventing and/or treating CVD complications. The invention additionally relates to kits comprising lipids and/or an antibody thereto, for use in the prediction and/or diagnosis of CVD complications. | 09-17-2015 |